cAMP-dependent protein kinase (PKA) · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14cAMP-dependent protein kinase (PKA) shows clinical signal disease relevance led by cancer. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P22694. Start with cancer, then reuse UniProt P22694 as the stable protein anchor across project notes and exports.
Start with cancer, then reuse UniProt P22694 as the stable protein anchor across project notes and exports.
cAMP-dependent protein kinase (PKA) shows clinical signal disease relevance led by cancer. 1 linked drug remains visible in the same block.
Start review with cancer because it currently carries clinical signal support. Linked drugs include GSK-690693. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxycAMP-dependent protein kinase catalytic subunit beta
Review this target as cAMP-dependent protein kinase (PKA), mapped to UniProt P22694. ChEMBL maps the protein component as cAMP-dependent protein kinase catalytic subunit beta. Sequence length is 351 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats cAMP-dependent protein kinase (PKA) as ChEMBL target CHEMBL2094138, mapped to UniProt P22694. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether cAMP-dependent protein kinase (PKA) is the right protein anchor across sources, using UniProt P22694 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | cAMP-dependent protein kinase (PKA) |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P22694 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | cAMP-dependent protein kinase catalytic subunit beta |
| UniProt Accession | P22694 |
| Component Type | Protein |
| Sequence Length | 351 aa |
cAMP-dependent protein kinase catalytic subunit beta
Review this target as cAMP-dependent protein kinase (PKA), mapped to UniProt P22694. ChEMBL maps the protein component as cAMP-dependent protein kinase catalytic subunit beta. Sequence length is 351 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
cAMP-dependent protein kinase (PKA) shows clinical signal disease relevance led by cancer.
Start review with cancer because it currently carries clinical signal support. Linked drugs include GSK-690693. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL213618 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL5183651 | 10.0 | Kd | 0.1 | Preclinical |
| CHEMBL388978 | 9.15 | IC50 | 0.7 | Preclinical |
| CHEMBL207544 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL3613610 | 8.96 | IC50 | 1.1 | Preclinical |
| CHEMBL383264 | 8.68 | IC50 | 2.1 | Preclinical |
| CHEMBL3613609 | 8.66 | IC50 | 2.2 | Preclinical |
| CHEMBL3613599 | 8.59 | IC50 | 2.6 | Preclinical |
| CHEMBL5188493 | 8.59 | IC50 | 2.6 | Preclinical |
| CHEMBL3613605 | 8.57 | IC50 | 2.7 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein format | 218 | 305 | 6.0 |
| cell-based format | 15 | 1 | 5.1 |
| assay format | 1 | 1 | 5.4 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 4 | 3 | 5.5 |
| cell-based format | 2 | 0 | — |